Gerardus P. J

Nov 5, 2024 | link.springer.com | Van Den Hout |Gerardus P. J |Van Laake

Dear Editor,With great interest we read the systematic review by Wiethoff et al. regarding the cost-effectiveness of therapies for inherited cardiomyopathies [1]. Left ventricular assist devices (LVADs) have demonstrated a significant survival benefit in patients with end stage heart failure (HF). To our surprise, the infographic (Fig. 1) in their review suggests that LVADs are not cost-effective in patients with dilated cardiomyopathy.

Aug 13, 2024 | link.springer.com | Van Den Hout |van der Meer |Peter-Paul M |Gerardus P. J

AbstractA left ventricular assist device (LVAD) is a life-saving but intensive therapy for patients with end-stage heart failure. We evaluated the healthcare consumption in a cohort of LVAD patients in our centre over 6 years. All patients with a primary LVAD implantation at the University Medical Centre Utrecht in Utrecht, the Netherlands from 2016 through 2021 were included in this analysis.